Adial Pharmaceuticals Inc
$ 1.58
1.28%
24 Apr - close price
- Market Cap 2,227,600 USD
- Current Price $ 1.58
- High / Low $ 1.59 / 1.55
- Stock P/E N/A
- Book Value 4.75
- EPS -11.93
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.83 %
- ROE -1.71 %
- 52 Week High 21.38
- 52 Week Low 1.51
About
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.
Analyst Target Price
$25.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-26 | 2025-11-13 | 2025-08-13 | 2025-05-12 | 2025-03-31 | 2024-11-12 | 2024-08-13 | 2024-05-14 | 2024-02-20 | 2023-11-14 | 2023-08-21 | 2023-05-12 |
| Reported EPS | -11.48 | -0.08 | -0.18 | -0.34 | -0.15 | -0.38 | -0.59 | -0.62 | -1.35 | -1.18 | 0.96 | -0.11 |
| Estimated EPS | -2.13 | -0.39 | -0.39 | -0.495 | -0.33 | -0.44 | -0.53 | -0.33 | -0.76 | -1.13 | -1.5 | -0.14 |
| Surprise | -9.35 | 0.31 | 0.21 | 0.155 | 0.18 | 0.06 | -0.06 | -0.29 | -0.59 | -0.05 | 2.46 | 0.03 |
| Surprise Percentage | -438.9671% | 79.4872% | 53.8462% | 31.3131% | 54.5455% | 13.6364% | -11.3208% | -87.8788% | -77.6316% | -4.4248% | 164% | 21.4286% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADIL
2026-04-24 18:39:58
The financial content for the article titled "Why did Adial Pharmaceuticals stock plunge over 20% after hours today?" is not available in the provided input. Therefore, it is impossible to summarize the reasons behind the stock plunge or any other details related to Adial Pharmaceuticals. The content only states "MSN", which does not provide any actionable information.
2026-04-23 19:10:14
Adial Pharmaceuticals announced it has completed demonstration batch production for its lead candidate AD04, an Alcohol Use Disorder (AUD) treatment, validating the manufacturing process for its planned Phase 3 clinical trials. This milestone allows the company to proceed with large-scale production and provides data for its investigational new drug application. Adial also recently entered a collaboration framework with Molteni Farmaceutici for AD04's commercialization in Europe.
2026-04-22 14:04:52
Adial Pharmaceuticals announced the completion of a demonstration batch production for AD04, its investigational drug for Alcohol Use Disorder. This batch met specifications for the planned Phase 3 clinical trial and matched previous phase 2 results, allowing the company to proceed with clinical and registration batches. Despite the stock trading near its 52-week low, analysts have price targets ranging from $8 to $42.
2026-04-22 13:48:52
Adial Pharmaceuticals has successfully completed the demonstration batch production for AD04, its lead investigational drug for Alcohol Use Disorder (AUD), confirming the process meets specifications for Phase 3 clinical trials. This successful technical transfer is crucial for producing clinical and registration batches, and for updating IND data with the FDA. The company's CEO, Cary Claiborne, emphasized that this milestone will aid ongoing discussions with the FDA and advance AD04's strategic development, which also has potential for treating other addictive disorders.
2026-04-22 13:39:52
Adial Pharmaceuticals announced the successful completion of a demonstration batch production for AD04, its lead drug candidate for Alcohol Use Disorder (AUD). This achievement validates the manufacturing process and positions the company to advance towards a planned Phase 3 clinical trial for AD04, which also has potential applications for other addictive disorders. The successful transfer of manufacturing capabilities to a new CDMO is expected to improve efficiencies and ensure product quality, facilitating discussions with the FDA regarding the drug's regulatory pathway.
2026-04-22 13:39:52
Adial Pharmaceuticals has successfully completed a manufacturing milestone for its lead drug candidate, AD04, which is being developed for Alcohol Use Disorder. This achievement involves a successful demonstration batch that met targeted specifications and validated the manufacturing process, allowing the company to proceed with large-scale production for its upcoming Phase 3 clinical program. The milestone also supports regulatory progress with the FDA and follows a recent collaboration agreement with Molteni Farmaceutici for potential commercialization in Europe.
